Pfizer is considered a good medium- to long-term investment despite near-term challenges from COVID revenue normalization and upcoming patent expiries. The company’s new and acquired products are driving strong double-digit growth, helping to offset losses from COVID-related revenue declines and patent exclusivity losses. Pfizer is also implementing cost-restructuring initiatives aiming to save $9.7 billion by 2029, which should support earnings and margins during this challenging period. Additionally, a roughly 6% dividend yield and attractive valuation provide downside protection while growth and cost-saving strategies develop for future upside potential.
Pfizer's stock price on Pluang is trading close to its 52-week high at USD 28.70 compared to a low of USD 23.67, showing relative strength despite a slight 0.10% dip as of Sep 29, 2026, 13:51 WIB. The stock offers a 6% dividend yield, which contrasts with its moderate price movement and supports its appeal during this phase of growth and cost-cutting initiatives. Investor sentiment on Pluang leans heavily bullish with 88% buy orders, reflecting confidence in Pfizer's medium- to long-term prospects amid current challenges.
Pfizer is rated a buy not because it is deeply undervalued now, but due to a disconnect between management's optimistic long-term growth outlook and the market's flat earnings expectations. While consensus models predict a revenue and earnings declin...
Pfizer faces significant revenue declines as key drug patents expire, but aims to maintain stable earnings through 2028 with a new drug pipeline and cost-saving measures targeting up to $4 billion in savings. The company projects 2026 revenues of $61...
